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Abstract
Adaptive immunity to Mycobacterium tuberculosis controls progressive bacterial growth and disease but does not eradicate
infection. Among CD4+ T cells in the lungs of M. tuberculosis-infected mice, we observed that few produced IFN-c without ex
vivo restimulation. Therefore, we hypothesized that one mechanism whereby M. tuberculosis avoids elimination is by
limiting activation of CD4+ effector T cells at the site of infection in the lungs. To test this hypothesis, we adoptively
transferred Th1-polarized CD4+ effector T cells specific for M. tuberculosis Ag85B peptide 25 (P25TCRTh1 cells), which
trafficked to the lungs of infected mice and exhibited antigen-dependent IFN-c production. During the early phase of
infection, ,10% of P25TCRTh1 cells produced IFN-c in vivo; this declined to ,1% as infection progressed to chronic phase.
Bacterial downregulation of fbpB (encoding Ag85B) contributed to the decrease in effector T cell activation in the lungs, as a
strain of M. tuberculosis engineered to express fbpB in the chronic phase stimulated P25TCRTh1 effector cells at higher
frequencies in vivo, and this resulted in CD4+ T cell-dependent reduction of lung bacterial burdens and prolonged survival
of mice. Administration of synthetic peptide 25 alone also increased activation of endogenous antigen-specific effector cells
and reduced the bacterial burden in the lungs without apparent host toxicity. These results indicate that CD4+ effector T
cells are activated at suboptimal frequencies in tuberculosis, and that increasing effector T cell activation in the lungs by
providing one or more epitope peptides may be a successful strategy for TB therapy.
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Introduction
Even though its etiologic agent was discovered over 125 years ago,
tuberculosis remains a global scourge, killing 1.7 million people in
2009, at least L of whom were immunocompetent [1]. Long-term
persistence of Mycobacterium tuberculosis, which resides principally in
phagocytic cells within the lungs, results in a chronic infection despite
the presence of an apparently appropriate adaptive immune
response. In mice infected with virulent M. tuberculosis, the early
phase of infection proceeds with unchecked bacterial growth until day
17–21 post-infection, when adaptive immunity finally exerts control
of bacterial growth in the lungs. Control of infection in both humans
and mice critically depends on M. tuberculosis-specific CD4+ Th1 cell
responses, which include production of IFN-c [2,3]; however
adaptive immune responses do not eradicate the infection.
Several potential mechanisms may account for the failure of
adaptive immune responses to eradicate the bacteria in tubercu-
losis. Generation of M. tuberculosis-specific CD4+ effector T cells is
delayed compared with responses to other pathogens [2,4]. In
addition, certain individuals, or strains of mice, may develop
inappropriate (e.g., Th2) [5,6] or imbalanced effector phenotypes
such as Th1/Th17 [7] in response to infection. However, even in
humans or mice that develop Th1 responses, a failure of CD4+
effector T cells to recognize infected cells may preclude their
optimal activation and limit induction of effector functions in the
lungs. Prevention of effector T cell activation could result from
impaired antigen presentation by lung APCs containing M.
tuberculosis [8,9,10] or because the antigens that effector T cells
recognize are not expressed or otherwise available in the lungs.
Furthermore, host regulatory mechanisms that limit immune
pathology, such as T regulatory cells [11], production of inhibitory
cytokines [12], and, possibly, onset of T cell exhaustion [13,14]
may inhibit the activity of effector T cells at the site of infection.
Finally, even when CD4+ effector T cells are activated, the efficacy
of these responses may be limited by the impaired ability of
infected cells to respond to IFN-c [15,16,17], induce phagosome
maturation [18,19], or undergo apoptosis [9,20,21,22]. Under-
standing the contribution of each of these potential mechanisms
limiting adaptive immunity to M. tuberculosis is an essential
prerequisite for vaccine design and other immunologic approaches
to tuberculosis prevention and therapy.
Here, we report that CD4+ effector T cells are activated at
submaximal and suboptimal frequencies in the lungs during M.
tuberculosis infection, that this is due in part to bacterial modulation of
antigen expression, and that increasing the availability of a single
antigen results in improved immune control of M. tuberculosis.
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Results
Prevalence of CD4+ T cells activated to produce IFN-c in
the lungs of M. tuberculosis-infected mice
We hypothesized that M. tuberculosis evades adaptive immunity
by modulating the activation of CD4+ effector T cells at the site of
infection in the lungs. Since in vitro studies have revealed evidence
that M. tuberculosis modulates MHC class II antigen presentation
[10,23,24,25,26], we focused on in vivo activation of CD4+ T cells
in the lungs. We reasoned that, if M. tuberculosis-infected cells do
not present antigens efficiently to effector T cells in the lungs, then
the frequency of activation of effector functions of CD4+ cells
would also be low at the site of infection. To test this, we used
direct intracellular cytokine staining of lung cells from infected
mice for IFN-c, without ex vivo restimulation. We found that that
the frequency of IFN-c expression by CD4+ T cells in the lungs
varied with the time of infection (Figure 1B). IFN-c+ CD4+ cells
were undetectable in the lungs at day 14, increased in frequency
beginning by day 21 to a peak at day 35 post-infection, and then
markedly decreased afterward; no more than 7% of the bulk
population of CD4+ T cells expressed IFN-c at any time point
after infection, and fewer than 1% expressed IFN-c during the
chronic phase. Other studies investigating IFN-c production by
CD8+ T cells in vivo have used treatment of mice with brefeldin A
or inclusion of brefeldin A during cell isolation and staining
[27,28]. However, we determined that these methods did not
improve detection of intracellular IFN-c by CD4+ T cells during
M. tuberculosis infection (Figure S1). These data indicate that a
small minority of polyclonal CD4+ T cells recruited to the lungs of
M. tuberculosis-infected mice are activated to produce IFN-c at a
given time, and are consistent with defective antigen presentation,
costimulation, and/or inhibition of effector T cell activation at the
site of infection.
Quantitating antigen-specific effector Th1 cell responses
in the lungs of M. tuberculosis-infected mice
Since the low frequency of CD4+ T cell expression of IFN-c in
the lungs of M. tuberculosis-infected mice could be due to the
presence of effector cells that traffic to the lungs but are not specific
for M. tuberculosis antigens, we performed the remainder of our
studies using CD4+ TCR transgenic T cells that specifically
recognize a well-characterized immunodominant M. tuberculosis
antigen. To quantitate the frequency of activation of M. tuberculosis
antigen-specific effector cells in the lungs, we prepared CD4+ Th1
effector cells (P25TCRTh1 cells) from transgenic mice with a
TCR specific for peptide 25 (amino acids 240–254) of Ag85B.
When P25TCRTh1 cells were incubated with irradiated spleno-
cytes in the absence of peptide 25, ,1.0% of the cells expressed
IFN-c as detected by intracellular staining and flow cytometry,
whereas addition of peptide 25 in vitro induced IFN-c expression
in ,90% of cells (Figure 2A). This result demonstrated that the
frequency of IFN-c staining in P25TCRTh1 cells can specifically
assay antigen dependent stimulation of P25TCRTh1 cells.
P25TCRTh1 cells recognize antigen at low frequency in
vivo
Since Day 21 post-infection corresponds to an acute stage of
infection when adaptive immune effector mechanisms have been
initiated and reduce the rate of bacterial population growth in the
lungs, and since it resembles the stage of LCMV infection in which
a high frequency of antigen-specific CD8+ T cell responses are
observed [28], we chose this time point for initial characterization
of P25TCRTh1 cell responses in vivo. We verified that adoptively
transferred P25TCRTh1 cells traffic to the site of infection by
examining sections of lungs from infected mice that had received
CFP+ P25TCRTh1 cells. CFP+ cells were abundant in the lung
parenchyma, and were concentrated in granulomas (Figure 2B).
Furthermore, we determined that .85% of the transferred cells
were protected from labelling by an i.v. injection of PerCP-labeled
Figure 1. Low frequency of IFN-c-producing endogenous CD4+
T cells in lungs of M. tuberculosis-infected mice. A. Frequency of
IFN-c expression by endogenous, polyclonal CD4+ T cells in the lungs of
M. tuberculosis-infected mice throughout infection, assayed by intra-
cellular cytokine staining without ex vivo restimulation. Flow cytometry
dot plots show lung CD4+ cells from a representative mouse at the
indicated time point post-infection. Values indicate the proportion of
cells expressing IFN-c in the CD4+ population for each mouse. B. Mean
frequency of IFN-c+ cells among lung CD4+ T cells for each group of 4
mice at each time point post-infection, assayed by intracellular cytokine
staining without ex vivo restimulation. Asterisks indicate statistical
significance of differences in frequency of T cell activation observed
between adjacent time points * p,0.05; ** p,0.005.
doi:10.1371/journal.ppat.1002063.g001
Author Summary
Mycobacterium tuberculosis causes persistent infection
even in human or animal hosts that develop antigen-
specific CD4+ and CD8+ T cell responses. To understand
this phenomenon, we tested the hypothesis that the CD4+
effector T cells that are generated in response to M.
tuberculosis infection fail to encounter their antigens at the
site of infection in the lungs. Using mice infected with M.
tuberculosis, and an assay of in vivo antigen-dependent
activation of CD4+ T cells, we found that both polyclonal
CD4+ and T cell receptor transgenic CD4+ T cells specific
for antigen 85B peptide 25 are activated at low frequencies
in the lungs. We found that this is due in part to
downregulation of antigen gene expression by M.
tuberculosis, as forced expression of the antigen gene
resulted in higher frequency activation of CD4+ T cells, as
well as CD4+ T cell-dependent reduction in bacterial
burdens and prolonged survival of infected mice. We also
found that administration of antigen 85B peptide 25,
which is recognized by a high proportion of M. tubercu-
losis-specific CD4+ T cells, reduced the bacterial burden in
the lungs, indicating that stimulation of existing antigen-
specific CD4+ T cells may be a promising approach to
therapy of TB.
Effector T Cell Activation in TB
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anti-CD4 antibody, indicating that adoptively transferred
P25TCRTh1 cells efficiently migrate out of the lung vasculature
into the parenchyma of infected lungs (Figure S2A).
To determine the frequency of activation of antigen-specific
CD4+ effector T cells in the lungs early in infection, we adoptively
transferred P25TCRTh1 cells on day 18 and harvested them on
day 21 after infection of wild-type mice with wild-type M.
tuberculosis H37Rv. The frequency of IFN-c+ P25TCRTh1 cells
isolated from the lungs was unexpectedly low at Day 21 post-
infection (Figure 2C and 2D). Approximately 1–2% of the
transferred P25TCRTh1 cells were stimulated to produce IFN-c
in vivo at that time point (Figure 2C), and this percentage was
similar to the frequency of total endogenous lung CD4+ T cells
expressing IFN-c on day 21 post-infection (Figure 1B, 2D).
Moreover, after intravenous injection of PerCP-labeled anti-CD4
antibody, the only IFN-c+ P25TCRTh1 cells identified were
PerCP negative (Figure S2B), indicating that the responding cells
were those that had migrated out of the vasculature into the lung
parenchyma and were protected from staining by the in vivo
injection of antibody.
We verified that stimulation of P25TCRTh1 cells to express
intracellular IFN-c is due to recognition of Ag85B peptide 25 by
transferring P25TCRTh1 cells into mice infected with an Ag85B-
null strain of M. tuberculosis (DAg85B), which is equivalent to wild-
type H37Rv in virulence [2]. A lower mean percentage (0.74%) of
P25TCRTh1 cells isolated from DAg85B-infected mice expressed
IFN-c than those from H37Rv-infected mice (Figure 2C and 2D).
This indicates that in vivo IFN-c production by P25TCRTh1 cells
is antigen-dependent and not the consequence of inflammatory
cytokines present at the site of infection. We also evaluated several
alternative approaches to detecting effector T cell activation in the
lungs. P25TCRTh1 cells expressed both CD25 and CD44 prior to
adoptive transfer, which excluded their use in evaluating effector
cell activation in vivo. Surface expression of CD69 was induced
after adoptive transfer of P25TCRTh1 effector cells into H37Rv-
infected mice; however, we found similar induction of CD69 in
mice infected with DAg85B, indicating that it did not specifically
reflect antigen-dependent effector cell activation. This result,
together with evidence that CD69 can be induced by costimula-
tion and by certain cytokines present at the site of M. tuberculosis
infection [29,30,31], indicates that expression of intracellular IFN-
c is the most accurate reporter of antigen specific Th1 effector cell
activation in the lungs. Together, these results indicate that even
though they traffic efficiently to the site of infection, Ag85B
peptide 25-specific CD4+ effector cells are activated to execute
their Th1 effector function at low frequency in the lungs of M.
tuberculosis-infected mice.
P25TCRTh1 cells are capable of responding to antigen at
the site of infection
Although IFN-c production by P25TCRTh1 cells at day 21 was
dependent on Ag85B, the frequency of IFN-c+ cells was
surprisingly low in H37Rv infected mice. One possible explanation
for the low frequency of activation of effector cells is that their
cognate antigen is not available for recognition at the site of
infection. To test this hypothesis, we provided antigen in vivo by
injecting peptide 25 intravenously into mice that had been infected
21 days earlier. When P25TCRTh1 recipient, H37Rv-infected
mice received peptide 25 six hours prior to lung cell harvest, the
frequency of IFN-c+ P25TCRTh1 cells increased to 20–50%
(Figure 2C and 2D). Similarly, peptide 25 injection stimulated a
higher frequency of IFN-c expression by endogenous CD4+ T cells
from mice infected with H37Rv (Figure 2C and 2D), consistent
with prior evidence that peptide 25 of Ag85B is a dominant
Figure 2. P25TCRTh1 cells produce IFN-c in response to M.
tuberculosis Ag85B peptide 25. A. P25TCRTh1 cells were restimu-
lated in vitro with C57BL/6 splenocytes in the presence or absence of
peptide 25 and analyzed by flow cytometry for intracellular IFN-c. B.
CFP-P25TCRTh1 cells traffic to the lung parenchyma of M. tuberculosis-
infected mice. Th1 effector cells were transferred on day 25, and lungs
were harvested on day 28 postinfection. CFP-P25TCRTh1 cells (light
blue-green) are found in interstitial regions with a high density of DAPI-
stained nuclei, typical of the aggregates of macrophages, dendritic cells,
and lymphocytes observed at this stage of infection. Scale bar: 50 mm.
C. On day 18 post-infection, mice infected with either H37Rv (w.t.) or
DAg85B M. tuberculosis received P25TCRTh1 cells by adoptive transfer.
Lung cells were harvested 72 hours later (day 21). Transferred
P25TCRTh1 (CD45.2+) cells were analyzed by flow cytometry for
intracellular IFN-c. One group of mice received intravenous treatment
with Ag85B peptide 25 6 hours prior to lung cell harvest. Flow
cytometry dot plots from in vivo experiments show a representative of
four mice per group. D. Day 21 post-infection with either H37Rv or
DAg85B: mean percentage from four individual mice of P25TCRTh1 or
endogenous CD4+ T cells expressing IFN-c with or without in vivo
administration of Ag85B peptide 25.
doi:10.1371/journal.ppat.1002063.g002
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antigen in C57BL/6 mice infected with M. tuberculosis [32,33].
P25TCRTh1 cells transferred into DAg85B-infected recipients
were also stimulated at a higher frequency after intravenous
peptide 25 treatment, while endogenous CD4+ T cells from
DAg85B-infected mice did not respond to peptide 25 with
increased IFN-c expression (Figure 2D). The failure of endogenous
CD4+ T cells from DAg85B-infected mice to respond to peptide 25
injection reflects the absence of Ag85B peptide 25-specific effector
T cells generated in response to this infection. These results
indicate that the frequency of IFN-c+ P25TCRTh1 cells is an
accurate and specific measure of CD4+ effector T cell stimulation
in response to presentation of Ag85B peptide 25 in vivo. The
observation that in vivo IFN-c responses to peptide 25 injection
depend on the presence of previously-generated (endogenous or
transferred) peptide 25-specific effector T cells indicates that the
responses are not due to a nonspecific effect of the epitope peptide
on costimulation or responses of CD4+ T cells with specificity for
other antigens. In addition, they demonstrate that if antigen is
made available to them, adoptively transferred P25TCRTh1 cells
can respond to antigen in the infected lungs, and they provide
evidence against an exclusive role for T regulatory cells and/or
suppressive cytokines in limiting the activation of CD4+ effector
cells at the site of M. tuberculosis infection in the lungs.
To further characterize the in vivo assay system, and to evaluate
the possibility that low frequencies of P25TCRTh1 responses are
attributable to either competition for antigen by endogenous
CD4+ T cells and/or a dominant effect of T regulatory cells, we
specifically ablated endogenous T cells from M. tuberculosis-infected
CD4-DTR mice [34] prior to assaying P25TCRTh1 responses in
vivo. Compared to untreated mice, DT treatment reduced the
fraction of endogenous CD4+ T cells in the lung by an average of
48.9%, p = 0.0053 (Figure S3A). However, this had no effect on
the percentage of P25TCRTh1 cells activated to produce IFN-c
(Figure S3B). These results strongly suggest that the low frequency
of activation of P25TCRTh1 cells is caused neither by competition
for peptide 25:MHC II complexes by endogenous CD4+ T cells,
nor by the influence of T regulatory cells in the lungs. We
therefore conclude that the response of adoptively transferred
P25TCRTh1 cells is an accurate reflection of MHC II
presentation of Ag85B peptide 25 by lung APCs during infection.
Dynamics of M. tuberculosis-specific CD4+ effector T cell
responses during the course of infection
Adaptive immunity restricts progressive growth of M. tuberculosis,
but it does not eliminate the bacteria from the lungs, which results
in chronic infection in mice and latent infection in humans. To
determine whether suboptimal activation of M. tuberculosis-specific
T cells contributes to the ability of the bacteria to persist, we first
asked whether activation of P25TCRTh1 cells in the lungs
changes as infection progresses to a chronic phase. To compare
the frequency of effector T cell stimulation at various stages of
infection, we transferred P25TCRTh1 cells into H37Rv-infected
mice on day 11, 18, 25, 32, or 39 post-infection. Lung cells were
harvested 72 hours after transfer (day 14, 21, 28, 35, or 42 post-
infection) and analyzed by flow cytometry for intracellular IFN-c
without ex vivo restimulation. The proportion of P25TCRTh1
cells producing IFN-c was highest (,10%) on day 14 (Figure 3A
and 3C). These results indicate that during the acute stage of
infection, adoptively transferred P25TCRTh1 cells are stimulated
in the lungs at a frequency comparable to that of TCR transgenic
CD4+ effector cells at the site of injection of a protein antigen and
adjuvant [35]. In contrast, expression of IFN-c by endogenous
(CD45.22) CD4+ cells was rare (,0.1%) at that time point
(Figure 1B and 1C). The difference between transferred and
endogenous cell responses on day 14 is consistent with our
Figure 3. Peptide 25-specific T cell activation and fbpB expression decrease during chronic infection. A. Frequency of IFN-c production
by adoptively transferred P25TCRTh1 (CD45.2+) CD4+ cells in the lungs of M. tuberculosis-infected mice throughout infection, assayed by intracellular
cytokine staining without ex vivo restimulation. Flow cytometry dot plots show lung P25TCRTh1 cells which were adoptively transferred 3 days prior
to the indicated time point post-infection. Values indicate the proportion of cells expressing IFN-c among the CD45.2+, CD4+ population for each
mouse. B. CFSE proliferation profile of naı¨ve P25TCR-tg CD4+ T cells transferred into M. tuberculosis-infected wild type recipients on days 11, 17 or 35
post-infection. Mediastinal lymph node cells were isolated 7 days after adoptive transfer (days 18, 24, or 48 post-infection) and analyzed by flow
cytometry for CFSE dilution to measure proliferation. Histograms are representative of four individual mice per time point. C. The mean percentage of
P25TCRTh1 cells from four individual mice expressing IFN-c at each time point post-infection is compared with the expression of M. tuberculosis fbpB
mRNA as infection progresses to chronic phase. Copy number of fbpB mRNA for four individual mice at each time point was determined by RT-qPCR
and is normalized to constitutively expressed 16S rRNA.
doi:10.1371/journal.ppat.1002063.g003
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previous observation that initiation of adaptive immunity to M.
tuberculosis is delayed until day 11–14 post-infection, and
consequently, endogenous CD4+ effector T cells specific for M.
tuberculosis antigens are first detected in the lungs on day 17 post-
infection. [2].
The frequency of IFN-c production by P25TCRTh1 cells
progressively decreased from day 14 to day 42 post-infection,
indicating a decrease in the efficiency of peptide 25-specific T cell
stimulation as infection enters its chronic phase (Figure 3A and
3C). These results with TCR transgenic CD4+ effector cells closely
mimic the results observed with endogenous polyclonal CD4+ T
cells after day 14 post-infection (Figure 1B and 1C). Although
Ag85B peptide 25-specific responses reached an earlier peak and
decreased earlier than did those of endogenous polyclonal CD4+ T
cell responses, the results with the two cell populations were
similar, with endogenous CD4+ effector T cell responses also
diminishing by day 42 post-infection.
To determine whether activation of naı¨ve Ag85B peptide 25-
specific CD4+ T cells is also diminished in the later stages of M.
tuberculosis infection, we assayed the response of adoptively
transferred naı¨ve P25 TCR-Tg T cells in the lung-draining
mediastinal lymph nodes of H37Rv-infected mice at various time
points post-infection. 7 days after transfer, we harvested lymph
node cells and measured in vivo T cell proliferation by flow
cytometry using a CFSE dilution assay. The rate of naı¨ve
P25TCR-tg T cells was highest upon transfer into mice on day
18 post-infection, while fewer cells exhibited CFSE dilution at days
24 and 48 post-infection (Figure 3B). These results indicate that
decreased stimulation of P25TCRTh1 effector cells is also
accompanied by decreased generation of peptide 25 specific
effector T cells from naive cells at later stages of infection.
Progressive decreases of P25TCRTh1 cell activation
accompany decreased fbpB expression
Since treatment of infected mice with exogenous peptide 25
enhanced T cell responses, indicating that adoptively-transferred
P25TCRTh1 cells are capable of responding to antigen stimula-
tion in the lungs, we hypothesized that availability and/or
presentation of antigen is a limiting factor in the activation of
CD4+ effector T cells at the site of M. tuberculosis infection. To test
this hypothesis, we first investigated whether changes in the
expression of the M. tuberculosis gene that encodes Ag85B influence
the frequency of activation of P25TCRTh1 effector cells. We
found that the frequency of in vivo activation of P25TCRTh1 cells
mimicked the temporal pattern of expression of fbpB (which
encodes Ag85B) by M. tuberculosis in vivo (Figure 3C). This suggests
that reduced expression of Ag85B contributes to the low frequency
of activation of Ag85B-specific CD4+ effector cells in the lungs,
thus resembling previously-reported observations with Salmonella
FliC expression and FliC-specific CD4+ T cell responses [36].
Forced expression of fbpB induces greater P25TCRTh1
cell activation
To test the hypothesis that fbpB down-regulation contributes to
the submaximal frequency of CD4+ effector cell activation and the
limited efficacy of the Th1 response in vivo, we constructed a
recombinant strain of M. tuberculosis to express fbpB at high levels
during chronic infection. Using the DAg85B strain as a
background, we introduced a wild-type fbpB allele under control
of the hspX/acr/Rv2031c promoter to the M. tuberculosis chromo-
some via the pMV306 integrating vector. hspX is expressed at high
levels during chronic phase infection in an expression pattern
inverse to fbpB [37,38]. This strain (hspXp:fbpB, termed ‘‘CPE85B’’
for chronic phase expressed Ag85B) exhibited higher fbpB
expression compared to H37Rv in the lungs of mice after aerosol
infection (Figure 4A). The expression of fbpB measured by RT-
qPCR was approximately 10-fold higher (normalized for the
abundance of 16S rRNA) at day 21 post-infection for CPE85B
than for H37Rv. As the infection progressed to chronic phase (day
28–42 post-infection), fbpB expression from the native promoter
declined by approximately 100-fold while fbpB expression driven
by the hpsX promoter remained at nearly constant, higher levels
(Figure 4A). Increased fbpB gene expression in the CPE85B strain
was accompanied by markedly enhanced expression and secretion
of Ag85B protein when the hspX promoter was induced in
stationary liquid culture (Figure 4B).
To determine whether forced expression of fbpB in M. tuberculosis
results in increased presentation of Ag85B peptide 25 to CD4+ T
cells, we infected bone marrow-derived dendritic cells (BMDC)
with either H37Rv or CPE85B and compared their ability to
activate P25TCRTh1 cells in culture. At all APC:T cell ratios
examined, DCs infected with CPE85B induced significantly
greater amounts of IFN-c secretion from P25TCRTh1 cells than
did DCs infected with H37Rv (Figure 4C). To determine whether
forced expression of fbpB can increase the frequency of
P25TCRTh1 stimulation during H37Rv infection in vivo, we
compared the frequency of P25TCRTh1 cell activation in the
lungs of mice infected with either H37Rv or CPE85B. Compared
to cells from H37Rv-infected recipients, P25TCRTh1 cells from
CPE85B-infected mice produced IFN-c with a 2-fold (day 21) to 5-
fold (day 42) higher frequency (Figure 4D and E). These findings
indicate that forced expression of fbpB by M. tuberculosis increases
the proportion of P25TCRTh1 cells that are activated to produce
IFN-c in the lungs. By suppressing fbpB expression after the initial
stages of infection, wild-type M. tuberculosis can reduce the
frequency of activation of Ag85B-specific effector T cells.
Although expression of fbpB was maintained at high levels from
day 14 to day 42 post-infection, P25TCRTh1 cell stimulation in
CPE85B-infected mice was only two- to five-fold higher than in
mice infected with H37Rv, and decreased as infection progressed
to chronic stage, indicating that other mechanisms, such as
inhibition of antigen presentation and/or induction of regulatory
T cells, exist to limit the activation of CD4+ effector T cells in the
lung.
Forced expression of fbpB impairs bacterial persistence
during chronic infection
We reasoned that, if diminishing fbpB expression during chronic
infection limits effector T cell activation and thereby enables M.
tuberculosis to evade adaptive immunity, then constitutive expres-
sion of fbpB throughout infection should improve immune control
of infection. To test this hypothesis, we infected mice with either
H37Rv or CPE85B and quantitated M. tuberculosis CFUs in the
lungs throughout the course of infection. The rates of bacterial
growth for the two strains were indistinguishable prior to day 14
post infection (Figure 4F), indicating that expression of fbpB by the
hspX promoter does not attenuate M. tuberculosis in vivo during the
innate immune stage of infection, prior to recruitment of CD4+
effector T cells to the lungs. Indeed, the in vivo generation time of
the CPE85B strain (23.0 h) was slightly shorter than that of
H37Rv (26.4 h) during days 1–14 of infection (these are not
significantly different by nonlinear curve fit and F test). However,
at times corresponding to the adaptive immune phase of infection,
the bacterial burden of the CPE85B strain in the lungs was
approximately 10-fold lower than that of H37Rv (Figure 4F).
These results suggest that forced expression of fbpB partially
overcomes the antigen deficit that limits the activation of CD4+ T
Effector T Cell Activation in TB
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cells in the lung during chronic infection and allows greater
antimycobacterial efficacy of the adaptive immune response.
Chronic phase attenuation of CPE85B is dependent on
CD4+ T cells
The observation that CPE85B demonstrates a growth pattern
indistinguishable from H37Rv during the first two to three weeks
of infection, prior to onset of adaptive immunity, suggested that
CPE85B was not inherently attenuated for growth in vivo.
However, we considered the possibility that over-expression of
fbpB could cause attenuation of M. tuberculosis as a result of gene
dysregulation or toxicity of an overabundant Ag85B protein.
Notably CPE85B demonstrated a similar growth pattern to
H37Rv during in vitro shaking culture. Furthermore, under
conditions of hypoxic stationary culture, when Ag85B protein is
strongly expressed by CPE85B compared to H37Rv, the survival
of the CPE85B strain is not impaired compared with that of wild-
type bacteria (Figure 4B). Taken together, these findings imply
that impaired persistence of M. tuberculosis CPE85B in vivo is the
consequence of increased antigen presentation and activation of
CD4+ T cells, and not due to intrinsic attenuation of the CPE85B
strain in vitro or in vivo. We reasoned that if the decreased lung
bacterial burden of CPE85B compared with that of H37Rv is
attributable to increased antigen presentation and recognition by
CD4+ T cells, then the attenuated phenotype of CPE85B should
be abrogated in mice lacking CD4+ T cells. Indeed, whereas wild
type C57BL/6 mice infected with CPE85B survived significantly
longer than those infected with H37Rv (median survival.300 and
239 days, respectively; p = 0.0062), MHCIIKO mice, which lack
CD4+ T cells, exhibited indistinguishable susceptibility to infection
with the CPE85B and H37Rv strains (median survival 79 and 81
days, respectively; p = 0.425), (Figure 5A), clearly establishing that
in vivo attenuation of the CPE85B strain depends on MHC II
antigen presentation and CD4+ T cell responses. These results also
indicate that increased antigen expression, accompanied by
increased antigen-specific T cell activation, can enhance control
of M. tuberculosis without detectable detrimental effects, since wild-
type mice infected with the CPE85B strain survived longer than
mice infected with H37Rv.
Since MHC II-deficient mice are highly susceptible to M.
tuberculosis infection, this could potentially mask any hypothetical
CD4+ T cell-independent mechanisms of attenuation of the
CPE85B strain. We reasoned that, if mechanisms other than
increased CD4+ T cell recognition contribute to the lower burdens
of CPE85B, then this strain would not recover and grow normally
in the lungs when CD4+ T cells are depleted during the chronic
phase of infection. We infected mice with H37Rv or CPE85B and
allowed the infection to proceed for 28 days, when initial lung
CFUs were measured for each group. As expected, bacterial CFUs
for CPE85B were ,3 fold lower than H37Rv at this time point
(Figure 5B). The remaining mice in each infection group were
then treated with monoclonal antibody GK1.5 every 6 days until
Figure 4. Forced expression of fbpB enhances T cell activation and impairs bacterial persistence during chronic infection. A.
Expression of fbpB mRNA, normalized to 16S rRNA by H37Rv and CPE85B throughout in vivo infection, determined by RT-qPCR of bacteria in lungs.
Data points indicate the mean (6SEM) of 4 mice per time point. B. Bacterial population size of H37Rv or CPE85B in vitro culture before and after
stationary liquid incubation to induce expression of hspXp:fbpB. Columns represent the mean (6SEM) population size of three cultures for each strain.
Western blot shows Ag85B protein secreted into culture supernatants during stationary culture. C. Activation of P25TCRTh1 cells in vitro by bone
marrow derived DCs infected with H37Rv or CPE85B, measured by IFN-c ELISA. Columns represent the mean (6SEM) of 3 wells at the indicated
infected DC:T cell ratio. D, E. Activation of P25TCRTh1 cells during mouse infection with H37Rv or CPE85B. P25TCRTh1 cells were transferred into
infected mice on either day 18 or 39 post-infection. 3 days after adoptive transfer (day 21 or 42), lung cells were analyzed by flow cytometry for
intracellular IFN-c without ex vivo restimulation. (D) Data points indicate the frequency of cells expressing IFN-c among CD45.2+, CD4+ lung cells at
each time point. (E) Flow cytometry plots show lung P25TCRTh1 cells from a representative mouse at the indicated time point post-infection. Values
indicate the proportion of IFN-c+ cells among CD45.2+, CD4+ population. F. Bacterial population size throughout mouse infection with H37Rv or
CPE85B. Data points indicate the mean (6SEM) of 4 mice per time point.
doi:10.1371/journal.ppat.1002063.g004
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day 50 post-infection to deplete CD4+ T cells. After an initial lag,
in which neither bacterial strain expanded, both CPE85B and
H37Rv resumed growth in the lungs at indistinguishable rates
(Figure 5B). Taken together, these data provide strong evidence
that improved control of the CPE85B strain is attributable to
increased activation of Ag85B-specific CD4+ T cells, although we
cannot exclude the possibility that other factors contribute to the
lower lung burdens of CPE85B that appear after the development
of adaptive immunity.
Treatment with intravenous peptide 25 during chronic
infection reduces lung bacterial burden
Our observation that forced expression of fbpB increased the
frequency of Ag85B peptide 25-specific CD4+ T cells and reduced
the bacterial burden in the lungs (Figure 4D, 4E, and 4F), together
with our observation that injection of peptide 25 also increased
activation of CD4+ effector T cells at the site of infection (Figure 2B
and 2C) suggested that providing antigen by injection of peptide
25 might also result in improved immune control of infection. We
first determined the duration of increased IFN-c production by
adoptively transferred P25TCRTh1 cells or endogenous CD4+ T
cells after peptide 25 injection. The frequency of IFN-c cells was
highest in both 6 hours after treatment, and decreased to
approximately 20% of maximal levels by 24 hours after peptide
injection for both endogenous CD4+ and P25TCRTh1 cells
(Figure 6A). By 72 hours post-treatment, the frequency of IFN-c+
cells returned to levels observed in the absence of peptide 25
injection, indicating that the activating effect of peptide 25
treatment is remarkably transient, entirely dissipating within 3
days of the treatment. Despite the transient nature of this effect, we
found that treatment of M. tuberculosis H37Rv-infected mice with
peptide 25 (in the absence of adoptively transferred P25TCRTh1
cells) every 2–3 days from day 28 to day 45 post-infection reduced
lung bacterial burdens by 1.0560.406106 bacteria (p = 0.018)
compared with that in mice treated with OVA peptide, an
unrelated MHC II epitope (Figure 6B). Neither group of mice
displayed any signs of toxicity, even after repeated peptide
injections. These results indicate that during M. tuberculosis
infection, CD4+ effector T cells are not stimulated at their
maximum potential frequency at the site of infection in the lungs.
Because effector T cell responses progressively decrease during
chronic infection, and enhancing T cell responses with exogenous
peptide antigen improves immune clearance of M. tuberculosis, we
Figure 5. Forced expression of fbpB impairs M. tuberculosis in a
CD4+ T cell dependent manner. A. Survival of C57BL/6 and CD4+ T
cell-deficient MHCII KO mice after aerosol infection with H37Rv or
CPE85B. N$5 mice for each group. B. Bacterial population size in lungs
of mice infected with H37Rv or CPE85B after CD4+ T cell depletion with
monoclonal anti-CD4 antibody GK1.5. Antibody treatment was started
on day 28 post-infection and continued every 6 days until day 50. Data
points indicate the mean (6SEM) bacterial burden in 4 mice in each
infection group at each time point. Asterisks indicate statistical
significance between groups of mice at neighboring time points within
one infection group; * p,0.05; ** p,0.005.
doi:10.1371/journal.ppat.1002063.g005
Figure 6. Treatment with peptide 25 transiently enhances CD4+ T cell responses and reduces bacterial burden. (A) Frequency of
adoptively transferred P25TCRTh1 (top row) or endogenous (bottom row) CD4+ T cells producing IFN-c at various time points after intravenous
treatment with synthetic Ag85B peptide 25. Flow cytometry dot plots show lung CD4+ cells from a representative mouse at the indicated time point
after treatment with peptide 25. Values indicate the proportion of IFN-c+ cells among the CD45.2+ or CD45.22, CD4+ population for each mouse. Data
shown are representative of n$4 mice per group. (B) Bacterial burden in the lungs of wild type mice treated from day 28 to day 45 post-infection
with intravenous Ag85B peptide 25 or OVA peptide control. Data points indicate the final bacterial population size for individual mice in each group
after treatment with either peptide. Data shown are representative of n$4 mice per group.
doi:10.1371/journal.ppat.1002063.g006
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conclude that failure to optimally activate effector T cells at the site
of infection is an important determinant of the limited efficacy of
adaptive immunity in tuberculosis.
Discussion
M. tuberculosis evades adaptive immunity to persist in the lungs,
often for the lifetime of the host. Here, we have characterized one
mechanism by which this impressive feat of immune evasion is
accomplished in vivo. We found that, of the large number of CD4+
effector T cells recruited to the lungs of infected mice, few are
stimulated to produce IFN-c (Figure 7A). While there are few
precedents available for comparison, our findings are in stark
contrast to those found in C57BL/6 mice infected with the
Armstrong strain of LCMV [28]. In that context, which results in
CD8+ T cell-dependent resolution of infection, .20% of virus-
specific CD8+ T cells are activated to produce IFN-c during the
acute stage of infection when viral burdens and antigen availability
are highest, and the frequency of in vivo-activated virus-specific
CD8+ T cells does not decrease until the viral burden is reduced.
We found that the initially low proportion of CD4+ T cells
producing IFN-c in the lungs of M. tuberculosis-infected mice
diminishes further as infection progresses to chronic phase, even
though the bacterial burden in the lungs remains high. Our studies
using adoptively transferred Ag85B-specific P25TCRTh1 cells
revealed that the decreasing responses of CD4+ effector cells are
caused in part by decreasing expression of fbpB by M. tuberculosis.
By reducing fbpB expression during chronic infection, M.
tuberculosis restricts the availability of Ag85B, an immunodominant
antigen, and thereby prevents infected APCs from optimally
activating CD4+ effector T cells. Consistent with this model, we
found that a recombinant strain of M. tuberculosis engineered to
maintain the expression of fbpB at high levels during chronic
infection (CPE85B) was attenuated during the chronic phase of
infection in a strictly CD4+ T cell dependent manner, indicating
that down-regulation of fbpB and limitation of antigen availability
is important for evasion of adaptive immunity by M. tuberculosis.
Treatment of infected mice with synthetic Ag85B peptide 25 also
increased CD4+ effector T cell IFN-c responses and significantly
reduced the bacterial burden in the lungs. We conclude that
suboptimal effector T cell activation enables M. tuberculosis to evade
elimination by adaptive immunity during the chronic stage of
infection, and that some of this suboptimal effector T cell
activation is attributable to restricted antigen expression by the
bacteria. In addition, other mechanisms that limit effector T cell
activation, such as interference with the MHC class II antigen
processing and presentation pathway and/or the action of
regulatory T cells, likely contribute to the remarkable survival of
M. tuberculosis in vivo.
Infection with M. tuberculosis induces a robust T cell response
involving CD4+ and CD8+ T cells and the effector cytokines IFN-c
and TNF [3], which are all essential for control of infection [5,39],
yet adaptive immunity fails to eradicate M. tuberculosis. Mecha-
nisms for the limited efficacy of the adaptive immune response in
tuberculosis fall into two general (not mutually exclusive)
categories: either the effector functions that T cells perform (e.g.
IFN-c production) are not effective because of failed responses by
the infected cells targeted by effector T cells; or the T cells
Figure 7. Schematic diagram of CD4+ effector T cell activation at the site of M. tuberculosis infection. A. During the chronic stage of
infection, Ag85B-specific CD4+ effector cells are activated at low frequencies, at least part due to low bacterial expression of the antigen gene;
bacteria are able to persist due to the low frequency of effector cell activation. B. Administration of epitope peptide occupies previously-empty MHC
class II and/or displaces previously-bound peptides and provides antigen for recognition by pre-existing epitope-specific CD4+ effector cells, resulting
in their activation and consequent reduction of the lung bacterial burden.
doi:10.1371/journal.ppat.1002063.g007
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recruited to the site of infection do not optimally perform the
effector functions required for immune clearance. Regarding the
former, the ability of M. tuberculosis to resist and inhibit the TNF-
and IFN-c-induced microbicidal responses of the phagocytic cells
it infects is one documented component of its immune evasion
strategy in vivo [40]. However, our observation that only a small
fraction of the CD4+ effector T cells in the lungs is activated to
synthesize IFN-c provides new support for the latter explanation.
The potential causes of this mechanism include bacterial factors
and host regulatory mechanisms that directly impair effector T cell
function. As an example of a direct bacterial effect, mycobacterial
cell wall glycolipids have been found to impair CD4+ T cell
responses in vitro [41]. With regard to host regulatory mecha-
nisms, during mouse infection, T regulatory cells limit the ability of
adaptive immunity to restrict the bacterial population size in the
lungs [11,42]. Interleukin-10 (IL-10), whether expressed by
myeloid cells or T cells, provides an additional host regulatory
mechanism that inhibits T cell effector functions in tuberculosis, as
transgenic over-expression of IL-10 in infected mice impaired T
cell responses and caused an increase in bacterial CFUs [12], while
deletion of IL-10 causes enhanced control of infection [43],
indicating that T cell-directed suppressive factors can limit the
success of the adaptive immune response to M. tuberculosis. On the
other hand, CD4+ effector T cells at the site of infection may not
recognize or become activated optimally by APCs bearing M.
tuberculosis-derived peptide:MHC II complexes, a process that is
required for IFN-c production in peripheral tissues [35]. Recent
observations using live imaging revealed that a small fraction of
Leishmania major-infected macrophages interact with Leishmania-
specific CD4+ T cells in vivo [44] indicating that in certain
infections, effector T cells may not recognize infected cells
efficiently, and this may contribute to slow clearance or persistence
of infection. Suboptimal stimulation of CD4+ T cells could occur
via direct targeting and inhibition of MHC II antigen presentation
pathways in infected APCs, or as a result of the limited availability
of peptide T cell epitopes, a consequence of bacterial suppression
of antigen encoding genes, or a combination of these mechanisms.
In this study, we first determined that the frequency of
endogenous polyclonal CD4+ T cells producing IFN-c in the
lungs was surprisingly low, and varied during the course of
infection, with the highest responses during the acute stage and the
lowest responses observed as infection reached the chronic stage.
These reduced responses occur despite the presence of similar
numbers of bacteria in the lungs during these stages of infection.
To further understand the underlying mechanisms of the low
frequency of effector T cell activation in the lungs, we quantitated
CD4+ effector T cell responses to the peptide 25 epitope of M.
tuberculosis Ag85B, a secreted protein targeted by a large number of
M. tuberculosis-specific CD4+ T cells [45]. Ag85B is targeted by 5 of
the 9 novel tuberculosis vaccine candidates currently in clinical
trials [46], thus understanding its behavior and responses to it in
vivo has considerable importance for TB vaccine development.
The reduced expression of fbpB we observed is consistent with
regulation by the state of bacterial growth, though it may be
indirectly triggered by the onset of Th1 immunity, since expression
of fbpB is maintained in mice lacking IFN-c [38]. Because Ag85B
is a cell wall biosynthesis enzyme, down-regulation of fbpB has
been interpreted as a consequence of transition by M. tuberculosis
into a relatively stationary state. Alternatively, fbpB suppression
during chronic infection may also be an evolved bacterial immune
evasion mechanism that enables long-term persistence of M.
tuberculosis by limiting T cell activation. In support of this, we found
that forced expression of fbpB by the CPE85B strain during
chronic infection resulted in a higher proportion of P25TCRTh1
cells producing IFN-c than in H37Rv-infected mice. Other studies
have suggested but not directly examined the possibility that over-
expression of certain M. tuberculosis proteins (including Hsp70 and
ESAT-6) may cause attenuation of bacterial persistence by
increased immune recognition [47,48]. Our finding that poly-
clonal CD4+ effector T cell responses diminish in chronic infection
suggests that this may be a general phenomenon in tuberculosis.
Importantly though, the higher frequency of P25TCRTh1 cell
activation observed in CPE85B-infected mice diminished at a later
time point as it did in H37Rv infection, implying that other
mechanisms, especially impairment of MHC II antigen presenta-
tion by M. tuberculosis, exist to limit effector T cell activation during
chronic infection in vivo.
Several in vitro studies have found that M. tuberculosis subverts or
impairs antigen presentation by the cells it infects, limiting the
capability of infected APCs to activate antigen specific T cells
[8,10]. Initial observations include the finding that M. bovis BCG
survives in primary human macrophages that CD4+ T cells fail to
recognize [26] and that M. tuberculosis-infected THP-1 cells express
low amounts of surface MHC II [25]. Several mechanisms for
inhibition of MHC II antigen presentation have been character-
ized using a spectrum of mycobacterial strains and cell
components. Among these, impaired phagosome maturation, a
well-characterized component of the ability of M. tuberculosis to
survive in phagocytic cells [19], has been found to limit activation
of cathepsin D for efficient processing of mycobacterial antigens
[24], while inducing autophagy with rapamycin was recently
found to improve the efficacy of BCG and other live mycobacterial
vaccines, by enhancing presentation of mycobacterial antigens
[49]. Impaired expression of MHC II by macrophages after IFN-c
treatment was also observed after in vitro infection or treatment of
macrophages with certain mycobacterial cell components
[23,50,51,52,53]. This effect may involve prolonged signals
received through bacterial pattern recognition receptors (PRRs)
including TLR2, although we recently reported a TLR2
independent mechanism for impaired MHC II expression in
response to IFN-c [53,54].
These and other in vitro studies are consistent with our present
results and lend support for the hypothesis that APCs do not
efficiently stimulate CD4+ effector T cells in the lungs during M.
tuberculosis infection in vivo. Attempts to verify and explore the
significance of these in vitro findings with in vivo infection models
have been limited thus far, until the present paper. One study of
mouse infection with GFP-expressing M. bovis BCG found a
modest decrease in surface expression of MHC II on some
populations of lung APC that harbored intracellular bacteria when
compared to those that did not contain bacteria [55]. In contrast,
in a low dose aerosol infection of mice with GFP-expressing
H37Rv, we did not detect a difference in surface MHC II
expression between infected and non-infected APCs at various
time points post-infection; we also found that M. tuberculosis-
infected APCs isolated from the lungs expressed high levels of the
costimulatory molecules CD80 and CD86 [54]. Nonetheless, there
is evidence that the activation of M. tuberculosis-specific T cell
responses is impaired during in vivo infection, indicating that M.
tuberculosis may specifically impair presentation of its antigens
without decreasing overall surface expression of MHC II. One
recent study found that mice provided with CD4+ TCR-transgenic
effector T cells specific for the M. tuberculosis antigen ESAT-6 prior
to infection can restrict bacterial population size to a lower level
but cannot prevent establishment of infection [56]. Despite the
presence of this effector T cell population in the lungs from the
onset of infection, control of bacterial growth was delayed until 7
days post-infection. Likewise, despite mounting apparently normal
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anti-M. tuberculosis CD4+ T cell responses, infected mice and
humans treated with anti-mycobacterial drugs to eliminate
primary infection remain susceptible to reinfection [33,57]. These
studies indicate that susceptibility to persistent tuberculosis is more
likely due to failure to activate antigen-specific effector T cells,
rather than to insufficient development of antigen specific T cells
in response to infection.
We observed increased survival of wild type, but not CD4+ T
cell-deficient mice infected with the CPE85B strain when
compared to those infected with H37Rv, highlighting the
importance of enhanced T cell stimulation to the long-term
outcome of infection, and indicating that enhanced effector T cell
activation, through increased antigen availability, can be accom-
plished without detrimental effects. Moreover, our finding that
sustained expression of Ag85B during the adaptive immune phase
of infection was associated with a 2- to 5-fold increase in antigen-
specific CD4+ T cell activation, yet reduced the bacterial burdens
approximately 10-fold implies that a massive increase in effector T
cell activation is not necessary to significantly improve immune
control of tuberculosis. Future efforts to develop tuberculosis
therapies should therefore aim to bypass or overcome factors that
limit effector T cell activation including direct T cell suppression,
impaired antigen presentation, and bacterial gene regulatory
mechanisms. For example, we found that the chronic phase
antigen deficit resulting from bacterial suppression of fbpB could be
overcome by systemic treatment of infected mice with synthetic
peptide 25, which strongly but transiently enhanced CD4+ T cell
responses specific for this epitope and reduced the bacterial
burden. This result implies that the endogenous CD4+ T cells
generated in response to infection with M. tuberculosis and recruited
to the infected lungs can be stimulated to perform their effector
functions if they are provided antigen, resulting in improved
bacterial clearance (Figure 7B). The potential for anti-tuberculosis
therapies that aim to enhance existing T effector cell responses in
infected individuals with synthetically produced peptides encoding
known T cell epitopes remains unexplored; however, given the
steadily increasing prevalence of drug resistant M. tuberculosis, such
immunotherapeutic approaches to tuberculosis are an attractive
option. Although the consequences of increasing the activation of
existing T cell responses have not been widely tested, in the
context of certain highly monoclonal T cell responses, adminis-
tration of epitope peptides has caused rapid mortality of infected
or previously immunized mice [58,59]. However, despite these
findings and concerns about possible immunopathology induced
by hyperactivation of effector T cells in tuberculosis [60], we
observed no morbidity or mortality in infected mice repeatedly
treated with peptide 25, a result that encourages the continued
exploration of this therapeutic strategy. Future studies should also
aim to determine the host and bacterial regulatory mechanisms
that account for chronic phase suppression of fbpB and whether
genes encoding other immunodominant M. tuberculosis antigens
behave similarly. Identification of the elements of this host-
pathogen interaction may lead to the development of therapies
that target antigen gene suppression and inhibition of antigen
presentation and provide a novel strategy for overcoming bacterial
persistence in vivo, leading to better outcomes in M. tuberculosis-
infected individuals.
Methods
Mice
C57BL/6, B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+), and MHCII
KO mice for aerosol M. tuberculosis infection experiments were
either bred in the New York University School of Medicine
Skirball animal facility or purchased from Taconic Farms, Inc.
P25TCR-Tg mice, whose CD4+ T cells express a transgenic T-cell
antigen receptor that recognizes the complex of peptide 25 (aa
240–254) of M. tuberculosis Ag85B and the mouse MHC II allele I-
Ab were prepared on a C57BL/6 background, as previously
described [2,61]. All animal experiments were done in accordance
with procedures approved by the NYU School of Medicine
Institutional Animal Care and Use Committee and in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health under the Assurance of Compliance Number A3435-01.
M. tuberculosis in vitro growth and aerosol mouse
infection
Wild type M. tuberculosis H37Rv was originally obtained from
ATCC. Frozen stocks for aerosol infection and in vitro use were
prepared and stored at 280uC. GFP-expressing H37Rv and
Ag85B null (DAg85B) strains of M. tuberculosis were generated as
previously described [2,62]. M. tuberculosis cultures were grown in
10 mL Middlebrook 7H9 liquid medium supplemented with 10%
v/v albumin dextrose catalase enrichment and incubated under
shaking conditions at 37uC. Mice at 8–12 weeks of age were
infected with ,100 CFU of M. tuberculosis via the aerosol route
using an Inhalation Exposure Unit (Glas-Col) as previously
described [62]. To verify inoculum size, 3–5 infected mice were
euthanized 24 hours after infection and lungs were homogenized
and plated on Middlebrook 7H11 medium supplemented with
10% v/v albumin dextrose catalase enrichment. To determine
bacterial population size at time points post-infection, lungs were
homogenized, diluted in PBS+Tween-80 (0.5%), and added to
7H11 plates. Plates were incubated at 37uC for 3 weeks and single
colonies were counted. To determine M. tuberculosis survival in
stationary culture, 7H9 medium was inoculated with H37Rv or
CPE85B, grown in shaking conditions to saturation
(O.D.600.1.0), and initial CFUs were measured. Cultures were
then placed in stationary incubator at 37uC for 17 days, and final
CFUs were measured.
Fluorescent microscopy of frozen tissue sections
C57BL/6 mice were infected with M. tuberculosis H37Rv and on
day 25 post-infection received 16106 CFP+ P25TCRTh1 cells via
adoptive transfer. On 28 post-infection, lungs were perfused and
frozen in OCT before 5 mm sectioning and fixation in cold
acetone. Sections were stained with DAPI to label nuclei and
analyzed on a Leica DMRB fluorescent microscope (objective:
Leica PL Fluotar 206/0.50) equipped with a Spot RT digital
camera. Separate images for DAPI and CFP fluorescence were
acquired and merged using Spot software.
P25TCRTh1 CD4+ effector T cells
P25 TCR-Tg CD4+ Th1 effector cells were generated in vitro as
follows: naı¨ve CD4+ T cells were magnetically isolated from lymph
node cell suspensions of P25 TCR-Tg mice (or for fluorescent
microscopy, a P25TCR-Tg mouse expressing CFP under control
of the ubiquitin promoter) using CD4 (L3T4) microbeads and an
AutoMACS (Miltenyi Biotech). P25TCR-Tg CD4+ T cells were
co-cultured with irradiated C57BL/6 splenocytes in the presence
of mouse IL-12p70 (10 ng/ml), mouse IL-2 (5 ng/ml), anti-IL-4
neutralizing antibody (50 ng/ml), and synthetic peptide 25
(0.5 mM). Cells were cultured at 37uC with 5% CO2. On days 3
and 5 of culture, cells were split 1:3 with fresh media containing
IL-12p70, IL-2, and anti-IL-4, but no peptide 25. Cells were
washed with PBS and counted on day 7 of culture before use for in
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vitro or in vivo assays. For in vitro restimulation, P25TCRTh1
cells were co-cultured with irradiated C57BL/6 splenocytes for
24 hours in RPMI-10 in the presence or absence of peptide 25
(0.5 mM) or bone marrow derived dendritic cells infected with M.
tuberculosis (MOI: 0.1). Cells were collected and analyzed by flow
cytometry for intracellular IFN-c, or culture supernatants were
analyzed for IFN-c by ELISA. For in vivo experiments, 16106
P25TCRTh1 cells were injected via tail vein or retro-orbital sinus
into recipient mice at various time points post-infection. Cells were
routinely isolated from lungs of recipient mice 72 hours after
adoptive transfer and analyzed by flow cytometry.
Naı¨ve P25TCR-Tg T cell proliferation
36106 CFSE-labeled CD4+ T cells, harvested from the lymph
nodes of P25TCR-Tg mice were adoptively transferred into
infected recipients at various time points post-infection. 7 days
after adoptive transfer, mediastinal lymph nodes were harvested
from recipient mice and cells were analyzed for CFSE dilution by
flow cytometry.
Generation of CPE85B strain of M. tuberculosis
The Ag85B null strain of M. tuberculosis (DAg85B), previously
created by our lab from wild-type H37Rv [2], was used as a
background strain for generating CPE85B. Both the hspX
promoter sequence, consisting of 254 bp directly 59 of the hspX
start codon, as well as the fbpB open reading frame were amplified
by PCR from H37Rv genomic DNA. Each of these fragments was
ligated into the pMV306 integrating vector to create a
recombinant construct, whose sequence was verified by Sanger
sequencing performed by the NYU DNA sequencing facility.
DAg85B was grown in 7H9 liquid media and transformed with
this construct via electroporation. The reaction was plated on
7H11 plates containing 25 mg/ml kanamycin to select for bacteria
incorporating the construct into the M. tuberculosis chromosome.
Presence of the construct in kanamycin resistant colonies was
verified by PCR. Expression and secretion of Ag85B by CPE85B
was confirmed by SDS-PAGE and anti-Ag85B western blot of
supernatants from 7H9 liquid medium after stationary culture. For
stationary culture-induced expression of Ag85B by the CPE85B
strain, 10 mL cultures were grown to late phase (OD600,1.0) in
normal shaking conditions, then flasks were sealed and transferred
to a stationary incubator for .1 week before supernatants were
collected.
RT-qPCR of bacterial mRNA from infected mouse lungs
To quantitate expression of M. tuberculosis genes during mouse
infection, lungs of infected mice were rapidly placed into a solution
of RNAlater (Ambion) and stored overnight at room temperature
in accordance with manufacturer recommendations to allow
permeation of the tissue. Thereafter, samples for RNA isolation
were stored at 280uC. When comparing expression of genes at
various time points, tissues were transferred to TRIzol (Invitrogen)
and quickly homogenized using a Tissue Tearor homogenizer to
disrupt mouse cells. Lung homogenates were centrifuged to pellet
intact bacterial cells, and supernatants discarded. M. tuberculosis
pellets were disrupted with zirconia/silica beads, RNA was
extracted, and RT-qPCR was carried out as previously described
[37] with fbpB copy number normalized to the constitutively
expressed 16S rRNA and multiplied by a factor of 105. The
following RT-qPCR primers were used in this study. 16S rRNA:
RT 5-ATTACGTGCTGGCAACATGA-3, qPCR For 5-GCC-
GTAAACGGTGGGTACTA-3, qPCR Rev 5-TGCATGTCAA-
ACCCAGGTAA-3; hspx/acr/Rv2031c: RT 5-GAATGCCCTTG-
TCGTAGGTG-3, qPCR For 5-AGATGAAAGAGGGGCGC-
TAC3, qPCR Rev 5-TAATGTCGTCCTCGTCAGCA3; fbpB/
Rv1886c: RT 5-TCCTGGAACTTCAGGTTGCT-3, qPCR For
5-ACCCCCAGCAGTTCATCTAC-3, qPCR Rev 5-TTCCCG-
CAATAAACCCATAG-3.
Tissue processing and flow cytometry
To isolate cells from infected tissues for flow cytometry, mice
were euthanized with CO2 followed by cervical dislocation.
Tissues were removed and mechanically disrupted by mincing in
RPMI as previously described [62] or using a gentleMACS
dissociator (Miltenyi Biotec) in the manufacturer-recommended
HEPES buffer. Lung suspensions were incubated in Collagenase
D and DNase at 37uC with 5% CO2 for 30 minutes and cells were
isolated by forcing suspensions through a 70 mM cell strainer.
RBCs were removed by ACK lysis and live cells counted by trypan
blue exclusion. Cell suspensions were stained using the following
fluorescently-labeled antibodies (Biolegend, BD Pharmingen, or
eBioscience): anti-CD3 PE, anti-CD4 (L3T4) FITC, anti-CD45.2
PerCP, anti-CD45.1 Pacific Blue, anti-IFN-c (XMG1.2) APC, and
rat IgG1 APC isotype control. Flow cytometry was performed
using a FACSCalibur or LSR II (BD Biosciences) at the NYU
Cancer Institute Flow Cytometry and Cell Sorting facility.
Analysis of flow cytometry data was performed using FlowJo
software.
Detection of IFN-c-producing cells by direct intracellular
cytokine staining
To detect intracellular IFN-c produced by cells in vivo, a
protocol was developed based on a previous study [28]. In contrast
to this study, however, optimal detection of IFN-c producing cells
from the lungs of mice infected with M. tuberculosis did not require
treatment of mice with i.v. brefeldin A or inclusion of brefeldin A
in tissue processing buffers. Instead, after euthanasia, tissues were
rapidly placed on ice and all cell isolation steps except
collagenase/DNase digestion (37uC for 30 minutes) and ACK
lysis (room temperature for 5 minutes) were carried out quickly
and on ice. Cells were stained for surface markers at 4uC for
30 minutes followed by permeabilization and fixation with
Cytofix/Cytoperm (BD Biosciences) at 4uC for 20 minutes.
Finally, fixed cells were stained with anti-IFN-c or a rat IgG1
isotype control at 4uC for 30 minutes. Flow cytometry dot plot
gates for IFN-c+ cells were set based on comparison with isotype
control and unpermeabilized cells stained for IFN-c.
Total CD4+ T cell depletion
Mice were treated with an intra-peritoneal dose of 500 mg of
either monoclonal antibody GK1.5, which depletes CD4+ T cells,
or a rat IgG2b isotype control (LTF-2) every 6 days from day 28 to
Day 50 post-infection. Efficiency of CD4+ T cell depletion 6 days
after GK1.5 treatment was determined to be .95% by flow
cytometry of cell suspensions from lungs, spleen and blood. In
mice treated with LTF-2 isotype control, no differences were
observed in CD4+ T cell number or bacterial burden when
compared to untreated mice.
Selective ablation of endogenous CD4+ T cells
To determine the influence of endogenous CD4+ T cells on the
response of adoptively transferred P25TCRTh1 cells in vivo, a
system was developed to deplete endogenous CD4+ T cells
selectively from infected mice. Mice expressing Cre recombinase
under control of the CD4 promoter were crossed with those
carrying an inducible Diphtheria Toxin Receptor (iDTR) allele,
whose baseline expression is prevented by a stop codon flanked by
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loxp sites [34]. Progeny of this cross (CD4-DTR) carry CD4+ T
cells that are sensitive to Diphtheria Toxin mediated ablation.
CD4-DTR mice were infected with H37Rv and received daily
intraperitoneal doses of DT (100 ng) to ablate endogenous CD4+
T cells from day 21 to day 28 post-infection. The efficiency of
CD4+ T cell ablation in the lungs was determined by flow
cytometry to be 48.9%. P25TCRTh1 cells were adoptively
transferred on day 25 post-infection and the frequency of IFN-c
production was assessed on day 28 post-infection.
Assessment of intravascular and extravascular location of
adoptively-transferred P25TCRTh1 cells
On day 25 post-infection, wild-type mice infected with M.
tuberculosis H37Rv received P25TCRTh1 cells via adoptive
transfer. On day 28 post-infection, mice were treated intrave-
nously with 800 ng (at 4.0 ng/mL) PerCP-labeled anti-CD4 (RM4-
5). Fifteen minutes later, mice were euthanized and total lung cells
were stained with FITC-labeled anti-CD4 (GK1.5). Lung cells
stained by anti-CD4-PerCP were considered to be CD4+ T cells
residing in the intravascular compartment at the time of antibody
injection. Cells staining positive for anti-CD4-FITC and negative
for PerCP were considered to be CD4+ T cells residing in an
extravascular or parenchymal lung compartment protected from
labeling with intravenous antibody. IFN-c production in vivo was
assessed by intracellular staining of all cells with APC-labeled anti-
IFN-c as previously described.
Systemic treatment of mice with synthetic peptides
Mice were intravenously treated with 100 mg of Ag85B peptide
25 (FQDAYNAAGGHNAVF) or OVA peptide control (ISQAV-
HAAHAEINEAGR) in 100 ml sterile PBS via tail vein or retro-
orbital sinus. Peptides were synthesized by EZBiolab or Peptides
International to a purity of .95%.
Statistical analyses
Data shown are representative of 2 or more experimental
replicates. In all figures, error bars indicate mean 6 SEM. To
determine statistical significance when comparing experimental
values from two groups of mice, one- or two-tailed student’s t-tests
were routinely used, each where appropriate. To compare the
growth rate of H37Rv and CPE85B in vivo, a non-linear
regression analysis (curve fit) with F-test was used to determine
whether a single curve could account for both data sets. In mouse
survival experiments, Logrank test was used to evaluate statistical
significance when comparing survival of one mouse strain after
infection with either of the two bacterial strains. * = p,0.05;
** = p,0.005; n.s = not significant.
Supporting Information
Figure S1 Brefeldin A treatment does not improve detection of
IFN-c produced by CD4+ cells in vivo. Frequency of lung CD4+ T
cells on day 28 post-infection that stain with anti-IFN-c antibody
or isotype control. Mice infected with M. tuberculosis were treated
with 250 mg intravenous brefeldin A or left untreated. 6 hours
after treatment, lungs were processed on ice in buffer alone or in
buffer containing brefeldin A (20 mg/mL). Flow cytometry plots
show lung CD4+ cells from a representative mouse in two
experiments with n = 3 mice. Values indicate the proportion of
IFN-c+ cells among CD4+ population for each mouse.
(TIF)
Figure S2 Adoptively transferred P25TCRTh1 cells efficiently
enter lung parenchyma and produce IFN-c. A. The percentage of
P25TCRTh1 cells adoptively transferred into infected mice that
stain PerCP2 or PerCP+ after intravenous treatment with PerCP-
labeled anti-CD4. Histogram gates indicate the fraction of CD4+,
CD45.2+ lung cells that are either PerCP2 (parenchymal) or
PerCP+ (intravascular). B. The fraction of P25TCRTh1 cells from
parenchymal (left, PerCP2) or intravascular (right, PerCP+)
compartments that are activated in vivo to produce IFN-c.
(TIF)
Figure S3 Ablation of endogenous CD4+ T cells does not affect
IFN-c production by adoptively transferred P25TCRTh1 cells. A.
The frequency of (CD45.2+) endogenous CD4+ T cells among
total lung cells from CD4-DTR mice 28 days after infection. Mice
left untreated or were treated daily for 7 days prior to analysis with
diphtheria toxin to ablate endogenous CD4+ T cells. B. The effect
of endogenous CD4+ T cell ablation on the fraction of (CD45.1+)
P25TCRTh1 cells adoptively transferred on day 25 post-infection
that are activated in the lungs to produce IFN-c.
(TIF)
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